Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Tel...
January 27 2017 - 9:00AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) announced today that Caroline
Dorsa has joined the company’s Board of Directors. Given her
financial expertise, Ms. Dorsa will also participate on the Audit
Committee of the Board.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170127005144/en/
Caroline Dorsa (Photo: Business Wire)
Ms. Dorsa has held a number of senior management positions at
Merck & Co., Inc., including Senior Vice President of Marketing
Strategy and Integration, and Vice President and Treasurer, where
she also oversaw investor relations, financial planning for
manufacturing and tax. Most recently, as Executive Vice President
and CFO at Public Service Enterprise Group, Ms. Dorsa led the
finance, business development, and investor relations teams. She is
a Director of Biogen Inc. and Intellia Therapeutics, Inc., and a
trustee of the Goldman Sachs MLP Income Opportunities Fund and the
Goldman Sachs MLP and Energy Renaissance Fund.
“Caroline brings a great breadth of knowledge and experience as
a director on major boards and a senior executive at large
companies,” said Francis deSouza, Illumina President and Chief
Executive Officer. “Her deep understanding of the clinical space
will enable Caroline to make a significant contribution to Illumina
as we continue to pursue growth in our clinical markets.”
In addition to her service at Merck & Co., Inc. and at
Public Service Enterprise Group, Ms. Dorsa served as Senior Vice
President and CFO of Avaya, Inc. She received her B.A. from Colgate
University and her M.B.A. from Columbia University.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170127005144/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243IR@illumina.comorMedia:Eric
Endicott858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024